<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913507</url>
  </required_header>
  <id_info>
    <org_study_id>2018/14JUI/253</org_study_id>
    <nct_id>NCT03913507</nct_id>
  </id_info>
  <brief_title>Efficacy of a New Sweat Collection Support: Impact on Neonatal Screening and Early Treatment of Cystic Fibrosis</brief_title>
  <acronym>MACRODUCT-3710</acronym>
  <official_title>Efficacy of a New Sweat Collection Support: Impact on Neonatal Screening and Early Treatment of Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In nearly 25% of children under 3 months, the sweat test produces a quantity of sweat that
      does not meet international recommendations and is insufficient to allow reliable and
      reproducible biological analyzes in the sweat collected. In children between 3 and 12 months,
      this rate is about 10% when it should not exceed 5%. Insufficient amount of sweat prevents
      confirmation or reversal of the early diagnosis of cystic fibrosis and early treatment before
      irreversible complications of the disease.

      In this trial, a new support of sweat collection (Macroduct® Advanced Model 3710 Sweat
      Collection System, Wescor) will be tested with the goal to increase the amount of sweat
      collected during the sweat test, in comparison with the clinical routine method.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2018</start_date>
  <completion_date type="Anticipated">July 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>chloride concentration</measure>
    <time_frame>day 1</time_frame>
    <description>The volume and the chloride concentration will be analyzed for each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sweat</measure>
    <time_frame>day 1</time_frame>
    <description>sweat collected with sweat collection method (Macroduct® Advanced) Model 3710 SYS, Wescor) compared with that currently used in clinical routine.
The effectiveness criterion of the new Macroduct Advanced collector will be defined as follows: the new device tested will be considered effective if the insufficient amount of sweat levels obtained are smaller or equal to those recommended, i.e. if it is lower than 10% in children under 3 months and below 5% in children between 3 and 12 months.
The insufficient amount of sweat rates will be compared between the two methods.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>one group : patients with suspicion of cystic fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Macroduct® Advanced Model 3710 SYS, Wescor</intervention_name>
    <description>for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.</description>
    <arm_group_label>one group : patients with suspicion of cystic fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject aged of 2 days to 12 months

          -  Indication of a sweat test prescribed by a clinician in a context of neonatal
             screening

          -  Clinically stable

          -  Well hydrated

          -  Not under treatment with mineralocorticoids

        Exclusion Criteria:

          -  Subjects weighing less than 2 kg

          -  Subjects less than 48 hours old

          -  Presence of an acute infectious condition

          -  Presence of mineralocorticoid treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresinha Leal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresinha Teresinha</last_name>
    <phone>00 32 2 764 9473</phone>
    <phone_ext>9473</phone_ext>
    <email>teresinha.leal@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey REYNAERTS</last_name>
    <phone>00 32 2 764 9472</phone>
    <phone_ext>9472</phone_ext>
    <email>audrey.reynaerts@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

